Mostrar el registro sencillo del ítem
| dc.contributor.author | Boia, Raquel | |
| dc.contributor.author | Dias, Paul-AN | |
| dc.contributor.author | Galindo-Romero, Caridad | |
| dc.contributor.author | Ferreira, Hugo-D | |
| dc.contributor.author | Aires, Ines-D | |
| dc.contributor.author | Vidal-Sanz, Manuel | |
| dc.contributor.author | Agudo-Barriuso, Marta | |
| dc.contributor.author | Bernardes, Rui | |
| dc.contributor.author | Santos, Paulo-F | |
| dc.contributor.author | de-Sousa, Herminio-C | |
| dc.contributor.author | Ambrosio, Antonio-Francisco | |
| dc.contributor.author | Braga, Mara-EM | |
| dc.contributor.author | Santiago, Ana-Raquel | |
| dc.date.accessioned | 2025-12-03T11:15:56Z | |
| dc.date.available | 2025-12-03T11:15:56Z | |
| dc.date.issued | 2022-03 | |
| dc.identifier.citation | Boia R, Dias PAN, Galindo-Romero C, Ferreira H, Aires ID, Vidal-Sanz M, et al. Intraocular implants loaded with A3R agonist rescue retinal ganglion cells from ischemic damage. Journal of Controlled Release. marzo de 2022;343:469-81. | |
| dc.identifier.issn | 0168-3659 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/23033 | |
| dc.description.abstract | Retinal ganglion cell (RGC) loss underlies several conditions which give rise to significant visual compromise, including glaucoma and ischaemic optic neuropathies. Neuroprotection of RGCs is a clinical well-defined unmet need in these diseases, and adenosine A(3) receptor (A(3)R) activation emerges as a therapeutic pharmacological approach to protect RGCs. A porous biodegradable intraocular implant loaded with 2-Cl-IB-MECA (selective A(3)R agonist) was used as a strategy to protect RGCs. Drug-loaded PCL implants released 2-Cl-IB-MECA for an extended period and the released 2-Cl-IB-MECA limited glutamate-evoked calcium (Ca(2+)) rise in RGCs. Retinal thinning due to transient ischemia was not prevented by 2-Cl-IB-MECA-PCL implant. However, 2-Cl-IB-MECA-PCL implants decreased retinal cell death, promoted the survival of RGCs, preserved optic nerve structure and anterograde axonal transport. We further demonstrated that 2-Cl-IB-MECA-loaded PCL implants were able to enhance RGC function that was compromised by transient ischemia. Taking into consideration the beneficial effects afforded by 2-Cl-IB-MECA released from the PCL implant, this can be envisaged a good therapeutic strategy to protect RGCs. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | * |
| dc.subject.mesh | Adenosine A3 Receptor Agonists/pharmacology | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Ischemia/drug therapy | |
| dc.subject.mesh | Receptor, Adenosine A3/metabolism | |
| dc.subject.mesh | Retina/metabolism | |
| dc.subject.mesh | Retinal Ganglion Cells | |
| dc.title | Intraocular implants loaded with A3R agonist rescue retinal ganglion cells from ischemic damage | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 35131370 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S016836592200075X | |
| dc.identifier.doi | 10.1016/j.jconrel.2022.02.001 | |
| dc.journal.title | Journal of Controlled Release | |
| dc.identifier.essn | 1873-4995 |